Avistone Biotechnology is an oncology company focused on developing targeted therapies for patients with unmet medical needs, with a lead asset PLB1001 (Vebreltinib) that targets MET tyrosine kinase activity. PLB1001 recently received conditional approval from the NMPA for MET exon 14 skipping NSCLC in China. The company also develops PLB1004, an EGFR tyrosine kinase inhibitor including activity against EGFR exon20 insertion mutations. Avistone has built a commercial sales and marketing team covering 25 provinces, nearly 1,000 hospitals, and hundreds of commercial companies and retail outlets in China. The company plans to use recent financing to support clinical research and development, internal combination studies, accelerated screening of new molecules, and expansion of clinical studies and commercialization in the United States. Avistone positions itself to continue advancing its pipeline and commercialization efforts while expanding global clinical development.

Total raised

$140M

Funding rounds

1

Latest round

Series B

Latest activity

Jan 2024